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Summary
QUESTIONS UNDER STUDY: To (1) assess distinct
clusters of psychological distress and health-related quality
of life during the first 6 months following lung transplanta-
tion; (2) identify patients with poor psychosocial outcomes;
and (3) determine potential predictors regarding psycholo-
gical distress and health-related quality (HRQoL) of life at
6 months post-transplant.
METHODS: A total of 40 patients were examined for psy-
chological distress (Symptom Checklist short version-9)
and quality of life (EuroQOL five-dimension health-related
quality of life questionnaire) during their first 6 months
post-transplant. Hierarchical cluster analyses were per-
formed to identify specific types of post-transplant out-
comes in terms of psychological distress and HRQoL over
the first six post-transplant months. Correlational analyses
examined medical and psychosocial predictors of the out-
come at 6 months post-transplant.
RESULTS: Three distinctive clusters were identified, sum-
marizing either groups of patients with (1) optimal (35%),
(2) good (42%), and (3) poor outcome-clusters (23%). The
Abbreviations
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ECMO extracorporeal membrane oxygenation
EQ-5D EuroQOL five-dimension health-related quality of life
questionnaire
FEV1 forced expiratory volume in one second
HRQoL health-related quality of life
ICU intensive care unit
IPF interstitial pulmonary fibrosis
ISHLT International Society for Heart and Lung Transplantation
LOS length of hospital stay
SCL-K-9 Symptom Checklist short version-9
SF-36 Short Form Health Survey
latter tended to be older, to suffer from more severe disease,
to have more co-morbidities, to have had a prolonged in-
tensive care unit and/or hospital stay, to have more hospital
admissions and were more frequently treated with antide-
pressants post-transplant. Disease severity, length of stay,
quality of life two weeks post-transplant, hospital admis-
sions and use of antidepressants were strong predictors of
psychological distress and impaired health-related quality
of life at six months of follow-up.
CONCLUSION: Almost a quarter of the investigated pa-
tients suffered from elevated distress and substantially im-
paired HRQoL, with no improvements over time. Results
underscore the psychosocial needs of patients with poor
post-transplant outcomes.
Key words: lung transplantation; psychological distress;
health-related quality of life
Introduction
Lung transplantation is an established therapeutic option
for end-stage lung disease, yielding successful outcomes in
carefully selected patients characterised by reduced disab-
ility, extended survival and improved health-related qual-
ity of life (HRQoL) [1–3]. To date, more than 47 000 adult
lung transplants have been reported worldwide to the Re-
gistry of the International Society for Heart and Lung
Transplantation (ISHLT) [4], while in Switzerland more
than 700 lung transplants have been performed since 1992
[5]. During the last 20 years, overall patient survival has
progressively improved. From January 2000 to December
2011, a total of 240 lung transplants were performed at the
Zurich University Hospital with one-, three-, and five-year
survival rates of 87%, 75% and 69%, respectively, com-
parable to results of international high-volume programmes
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[6]. In Switzerland, there are two transplant centres per-
forming lung transplantations (University Hospital of
Zurich and University Hospital of Lausanne). The annual
number of lung transplantations in 2014 was 24 at the
transplant centre in Lausanne and 34 in Zurich [7].
To date, studies on psychosocial outcomes following trans-
plantation have primarily compared the post-operative
HRQoL trajectories of different types of solid organ trans-
plantation [8–10]. In these studies, recipients of different
solid organ transplants did not share the same HRQoL tra-
jectories. In particular, the HRQoL outcomes of lung trans-
plant recipients appeared to be inferior to those receiv-
ing other solid organs [9, 11]. Interestingly, most studies
looked at the entire group, and did not distinguish between
patients with improved postoperative HRQoL and patients
with similar or worse quality of life compared with their
pretransplant scores.
Understanding the predictive impact of psychosocial and
medical variables on post-operative HRQoL could be use-
ful when making choices regarding therapy. Although pre-
vious research has identified associations between
psychosocial and medical characteristics and post-trans-
plant HRQoL, the predictors of post-transplant HRQoL are
still not well described for lung transplant patients. There is
a paucity of consistent data regarding predictive factors for
post-transplant HRQoL [12]. In general, studies on predict-
ors of post-transplant HRQoL in lung recipients demon-
strate that bronchiolitis obliterans syndrome, the most com-
mon form of chronic lung allograft dysfunction, the ad-
verse effects of immunosuppressant medications, and pain
significantly reduce HRQoL and increase depressive symp-
toms [13–15]. In contrast, results on other potential out-
come predictors – including age, gender, psychiatric his-
tory, longer waiting times for transplantation and forced
expiratory volume in one second (FEV1) – have been con-
tradictory and supported only by single studies [1, 16-18].
In light of the above, it is of clinical relevance to assess
the psychosocial health of lung transplant patients to identi-
fy those at risk for unfavourable postoperative outcomes
and to make more informed therapeutic choices to enhance
patients’ symptom experience. The main objectives of the
current study were therefore: (1) to determine outcome
clusters of post-transplant psychological distress and
HRQoL of lung transplant recipients over the first 6 months
after lung transplantation; (2) to identify those lung recip-
ients with poor postoperative outcomes; and (3) to assess
potential short-term predictors and their impact upon psy-
chological distress and HRQoL. This subject has clinical
relevance with respect to the treatment of patients who un-
dergo lung transplantation but fail to experience any im-
proved quality of life.
Methods
Participants
Between January 2012 and April 2014, 72 lung transplants
were performed at the Transplant Centre at the University
Hospital of Zurich, Switzerland. All patients who received
transplants over this time period were considered to be eli-
gible for inclusion, unless they were: (1) younger than 18
years of age, (2) unable or unwilling to provide informed
consent, or (3) unable or unwilling to complete question-
naires in German. Forty-three consecutive adult lung trans-
plant recipients qualified for the study. During data col-
lection, three subjects in total unexpectedly withdrew from
participation for medical or personal reasons (e.g., feeling
overwhelmed by hospital routines and preparations for dis-
charge, distressed, overly-tired, and/or short of time). One
of these three patients had to be excluded owing to a critical
health condition and repeated hospitalisations in the intens-
ive care unit (ICU). The final sample included 40 patients
(fig. 1).
Design and procedures
In this prospective, longitudinal study, 40 lung transplant
recipients were examined at three different measurement
time-points (T1: 2 weeks; T2: 3 months; T3: 6 months
after transplantation) to capture specific types of outcome
clusters in terms of psychological distress and HRQoL over
the first 6 postoperative months. Following approval by
the Ethics Committee of the Canton of Zurich, Switzer-
land, all patients provided written informed consent prior
to their participation. Eligible patients were asked to com-
plete the same battery of questionnaires at every data col-
lection point. The initial assessment at T1 was performed
during hospitalisation, and the follow-up assessments at T2
and T3 typically were conducted during regular transplant
clinic out-patient visits at the University Hospital Zurich.
Few patients were still hospitalised or admitted to hospit-
al because of complications at T2 or T3. Demographic and
medical data were retrieved from patient medical records.
Medical data included the underlying diagnosis/indication
for transplantation, the presence of comorbid conditions,
the time on the waiting list, the number of days spent in the
ICU after transplantation, the length of hospital stay (LOS),
treatment with antidepressants, and the mortality rate over
the course of the data collection phase.
Figure 1
Patient recruitment.
LTx = lung transplantation; pLTx = post lung transplantation; T1–T3
= three measurement time-points.
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Measures
The Symptom Checklist (SCL-K-9)
The German version of the Symptom Checklist-Short form
(SCL-K-9) was used to assess overall psychological dis-
tress [19]. The SCL-K-9 [20] is comprised of nine items,
each rated on a five-point Likert scale ranging from 0 (not
at all) to 4 (very strong). According to the original glob-
al severity index, a mean score (0–4) for the nine items
was computed, with higher values indicating greater dis-
tress (the community-based standard value = 0.41). The
SCL-K-9 is highly correlated with the original SCL-90-R
[21] and offers similarly good psychometric properties and
sensitivity to change, with a Cronbach’s alpha of 0.87. In
our clinical sample, internal consistency of the SCL-K-9
over the three measurement points was good, with Cron-
bach’s alpha ranging from 0.75 to 0.84.
EuroQuol (EQ-5D)
All study subjects completed the EQ-5D, a five-item self-
administered survey instrument that measures HRQoL [22,
23]. The questionnaire covers five dimensions of health:
(1) mobility, (2) self-care, (3) usual activities, (4) pain/dis-
comfort, and (5) anxiety/depression. For each dimension,
patients selected one of three graded responses, indicating
no problems, some problems, or severe problems with the
activity. A single global EQ-5D score (range 0–100) was
generated by use of the sum model as describe by Hinz
et al. [23] (community-based standard value = 91.7). The
EQ-5D is used in studies to assess psychotherapeutic treat-
ment, where it has been shown to be valid, sensitive to
change, and responsive to improvements in mental health.
In the current study, the EQ-5D demonstrated acceptable
to good internal consistency over the three data collection
points, with Cronbach’s alpha ranging between 0.60 and
0.76. The lower level of internal consistency observed
across the different outcome measures might be explained
by the high level of homogeneity in our clinical sample.
Additionally, we used a pretransplant comorbidity index
developed by Barrios et al. [24], consisting of ten extrapul-
monary comorbidities that may have negatively impacted
short- and long-term postoperative trajectories. This co-
morbidity index included the following factors: (1) body
mass index >30 kg/m2, (2) osteoporosis, (3) insulin-de-
pendent diabetes, (4) arterial hypertension, (5) cardiac dis-
ease, (6) chronic liver disease, (7) diverticulosis, (8) gast-
roesophageal reflux, (9) history of malignancy, and (10)
psychiatric disorders. The comorbidity index was com-
puted by summing up the number of comorbidities for each
patient. Values between 0 and 10 were possible.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS, ver-
sion 22.0) was used to perform all statistical analyses, with
a two-tailed probability value of 0.05 considered statist-
ically significant [25]. Descriptive statistics were reported
as means and standard deviations, or as counts and per-
centages. Hierarchical cluster analysis was performed to
identify different post-transplant outcome clusters related
to psychological distress and HRQoL over the first 6 post-
operative months based on six variables (SCL-K-9 global
severity index and EQ-5D score measured at T1, T2 and
T3). All these variables were standardised prior to clus-
tering. Squared Euclidean distance as a proximity measure
and Ward’s minimum variance agglomerative method were
used [26]. The clustering process starts with the same num-
ber of clusters as cases, and reduces the number of clusters
step-wise using dissimilarities or distances between ob-
jects, that is, combining those clusters whose combination
results in a minimum increase in the total within-group sum
of squares. If a point is reached whereby clusters are com-
bined that are dissimilar, the within-group sum of squares
noticeably increases (as can be seen in the agglomeration
schedule). The number of clusters prior to this rapid in-
crease in the agglomeration coefficient is considered the
natural grouping scheme [27]. However, it must be taken
into account that this analysis was exploratory in nature,
and that the choice of the number of a cluster to extract
is somewhat arbitrary. Patients’ characteristics were com-
pared between the cluster groups using one-way analys-
is of variance (ANOVA), with Bonferroni post hoc test
to identify statistically significant differences between spe-
cific cluster groups. Moreover, to generate some appreci-
ation regarding the clinical significance of our results, ef-
fect sizes (Eta2 for interval scalded variables and Cramer’s
V for categorical variables) were computed according to
Cohen [28]. Values for Eta2 are categorised as small (0.01),
intermediate (0.06), or large (0.14) while for Cramer’s V, a
value of 0.1 is considered a small effect, 0.3 a medium ef-
fect and 0.5 a large effect. Pearson correlation coefficients
were calculated to identify relevant predictor variables of
psychological distress (SCL-K-9) and HRQoL (EQ-5D) 6
months post-transplant.
Results
Demographic characteristics
Detailed patient demographics and clinical characteristics
are summarised in table 1. The main indication for lung
transplantation in our clinical sample was chronic obstruct-
ive pulmonary disease (38%), followed by cystic fibrosis
(33%). With respect to employment status, 45% were not
working prior to transplant for health reasons, while 20%
were already retired. Six months after transplantation, all
40 patients were still alive.
Cluster analysis
The agglomeration coefficients generated by cluster ana-
lysis revealed a demarcation point between three- and four-
cluster solutions, suggesting that a four-cluster solution
best distinguished the groups with regard to post-transplant
psychological distress and HRQoL. However, a four-
cluster solution produced one cluster with only two pa-
tients. For statistical reasons, we therefore decided on a
three-cluster solution. An inspection of the clustering tree
(dendrogram) indicated a three-cluster solution to be ap-
propriate.
The resultant three-cluster solution generated relatively
well-sized groups related to psychological distress and
HRQoL over T1 – T3, labelled according to their most dis-
tinguishing characteristics (fig. 2). Cluster characteristics
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are displayed in table 2. Cluster A included those patients
with optimal postoperative outcomes over time (n = 17;
42%) in terms of a high EQ-5D and low SCL-K-9 scores
within 2 weeks of surgery. EQ-5D further improved over
the three data collection points and SCL-K-9 decreased
progressively. At 6 months post-transplant, these patients
reported HRQoL levels comparable to those of a
community-based sample (EQ-5D value of 91.7) [23] and
small but not significantly elevated SCL-K-9-values.
Cluster B included transplant recipients with good post-
operative outcomes over time (n = 14; 35%). In contrast
to Cluster A, patients of Cluster B were characterised by
considerably reduced EQ-5D and high SCL-K-9 scores
2 weeks after surgery, but significant improvements in
EQ-5D and SCL-K-9 at 6 months. EQ-5D-values at 6
Figure 2
Post-transplant outcome clusters in lung transplant recipients.
Plots A–C illustrate postoperative outcome clusters after lung
transplant determined by cluster analysis. The left y-axis represents
mean values for EQ-5D, while the right y-axis represents mean
values for global SLK-9 values. Higher values indicate higher
EQ-5D or poorer SCL-K-9 values, respectively. T1–T3 stand for the
three different measurement time points (T1: 2 weeks; T2: 3
months; T3: 6 months post-transplant).
EQ-5D = the EuroQOL five-dimension Health-Related Quality of
Life questionnaire; SCL-K-9 =Symptom Checklist short version-9
months of follow-up were slightly lower than those of the
healthy normal population. Cluster C incorporated trans-
plant recipients with poor post-operative outcomes over
time (n = 9; 23%), with both a low EQ-5D and high SCL-
K-9 score 2 weeks after transplantation, and only a small
gain in EQ-5D while SCL-K-9 scores remained steadily el-
evated over the remainder of the first 6 months of follow-
up.
Predictor analyses of post-transplant trajectory
For predictor analyses to distinguish the three groups of
clusters, the following demographic, clinical and psychoso-
cial characteristics were included: sex, age, underlying dia-
gnosis, disease severity, time on the waiting list, extracor-
poreal membrane oxygenation (ECMO) use (pretrans-
plant), comorbidities, number of days in the intensive care
unit (ICU), length of stay (LOS), number of hospitalisa-
tions, number of infections, number of rejections and use of
antidepressants within the first 6 months after lung trans-
plant (table 3). The median comorbidity index value across
the 40 patients was two and ranged between none and four
comorbidities. Thirty-five percent of the transplant recip-
ients suffered from three or more comorbidities. Signific-
ant intergroup differences were identified for LOS (Eta2 =
0.53), number of hospital admissions (Eta2 = 0.23) and use
of antidepressants (Cramer’s V = 0.53) within the first 6
months after lung transplant, with large effect sizes. No sig-
nificant cluster differences were evident for all other in-
vestigated variables. However, medium to large effect sizes
were found for age (Eta2 = 0.07), disease severity (Eta2 =
0.13), comorbidities (Eta2 = 0.06), and number of days in
ICU (Eta2 = 0.08), indicating that relative to patients of the
optimal or good cluster groups, those with poor postoper-
ative outcomes tended to be older, to suffer from consid-
erably more severe disease, to have more comorbid condi-
tions, and to have spent longer periods of time in the ICU
and hospital. No meaningful intercluster differences were
identified for patient gender, underlying diagnosis, time on
Table 1: Demographic and medical data of lung transplant recipients.
Variables 40 LTx-Recipients
n (%)
Male gender 22 (55)
Median age (range) 50 (20–68)
Education level
Elementary
Secondary
Tertiary
7 (17)
21 (53)
12 (30)
Married 17 (43)
Indication for LTx
COPD 15 (38)
Cystic fibrosis 13 (33)
Idiopathic pulmonary fibrosis 7 (17)
Other 5 (12)
ECMO use 13 (33)
Bilateral LTx 40 (100)
Retransplant 2 (5)
Average time on wait list (d) 270.5 (10–992)
Days in ICU (mean; range) 4 (2–29)
Weeks in hospital pLTx (mean; range) 4.5 (3–14)
COPD = chronic obstructive pulmonary disease; ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit; LTx = lung transplantation; pLTx = post-
transplant.
Original article Swiss Med Wkly. 2015;145:w14236
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waiting list, ECMO use prior to transplantation, or number
of infections or rejections post-transplant.
Predictor analyses for psychological distress and
HRQoL 6 months post-transplant
Table 4 presents the results of correlation analyses used to
identify associations between each potential outcome pre-
dictor and both the level of psychological distress (SCL-
K-9) and HRQoL score (EQ-5D) 6 months post-transplant.
Significant associations with the SCL-K-9 score at T3 were
evident for disease severity (r = 0.39; p = 0.001); length
of hospital stay (r = 0.44; p = 0.005), the EQ-5D score at
T1 (r = –0.37; p = 0.02), number of hospitalisations (r =
0.66; p = 0.01) and use of antidepressants (r = 0.47; p =
0.01) within the first 6 months post-transplant. The follow-
ing variables were significantly correlated with T3 EQ-5D:
disease severity (r = –0.42; p = 0.006); T1 EQ-5D (r = 0.39;
p = 0.01); number of days in the ICU (r = –0.36; p = 0.02);
length of hospital stay (r = –0.72; p = 0.001), number of
hospitalisations (r = –0.43; p = 0.01) and use of antide-
pressants (r = –0.63; p = 0.01) within the first 6 months
after lung transplant.
Discussion
In this study, a hierarchical cluster analysis was performed
– so as to identify distinctive post-transplant sub-groups re-
lated to psychological distress and HRQoL over those first
6 postoperative months. Our data revealed a three-cluster
solution, distinguishing transplant recipients manifesting
optimal, good and poor postoperative clusters. Transplant
recipients of the optimal postoperative cluster (42%) repor-
ted surprisingly high HRQoL levels and notably low levels
of psychological distress shortly after transplantation, and
by 6 months post-transplant, their reported HRQoL and
stress levels were similar to healthy population values. Pa-
tients in the good cluster (35%) experienced impaired
HRQoL and elevated stress levels 2 weeks after transplant-
ation, but by 3 months follow-up reported significantly in-
creased HRQoL and significantly reduced psychological
distress. This group of patients benefitted most from lung
transplant surgery by demonstrating substantial improve-
ments in HRQoL dimensions and levels of psychological
distress over the first 6 months after transplantation com-
pared with the other two cluster groups. Importantly to
note, almost a quarter of our clinical sample (23%) showed
poor postoperative outcomes over time, suffering from el-
evated stress levels that continued to remain high over
the first 6 months post-transplant, and experiencing only
slightly increased HRQoL that remained low throughout
the six-month observation period. Most investigations on
psychosocial outcomes after lung transplantation have fo-
cused on the average value of HRQoL and did not distin-
guish between favourable and poor postoperative outcome.
However, lung transplant recipients are a heterogeneous
group of patients and do not necessarily experience the
same improvements in health status. The use of cluster
analyses instead of considering only outcomes at discrete
measurement time points is beneficial for identifying pa-
tients who did not experience significant improvements of
postoperative HRQoL. Our results indicate that lung trans-
plant recipients respond in different ways to their surgery
and that quality of life gain after transplantation varies
greatly from patient to patient. The majority of patients
appear to cope very well, while others seem to struggle
postoperatively. For many patients, the transplantation it-
self, as well as the ICU stay, might be perceived as a trau-
matic stressor that can decrease HRQoL and trigger men-
tal distress [29]. Additionally, the rehabilitation period can
vary greatly from patient to patient. A lung recipient’s own
history of lung disease plus enduring functional impair-
ments and symptom distress post-transplant may negat-
ively affect the patient’s HRQoL perception [30]. Further-
more, the concept of resilience might explain at least some
of the different responses to transplantation. For instance,
previous studies in transplant medicine illustrated that a
high degree of resilience and self-efficacy [31] as well as
Table 2: Cluster characteristics.
Optimal cluster (A)
n = 17 (42%)
Good cluster (B)
n = 14 (35%)
Poor cluster (C)
n = 9 (23%) Between groups
Time-point
instrument
Mean (SD) Mean (SD) Mean (SD) p-value Bonferroni post hoc test p-value
T1
SCL-K-9
0.5 (0.2) 1.7 (0.6) 0.8 (0.3) <0.001 A vs B
A vs C
B vs C
<0.001
0.105
<0.001
T1
EQ-5D
80.6 (14.3) 53.6 (13.4) 46.7 (21.1) <0.001 A vs B
A vs C
B vs C
<0.001
<0.001
0.937
T2
SCL-K-9
0.2 (0.2) 0.6 (0.3) 1.0 (0.4) <0.001 A vs B
A vs C
B vs C
0.008
<0.001
0.004
T2
EQ-5D
93.5 (4.9) 83.6 (12.2) 66.7 (17.3) <0.001 A vs B
A vs C
B vs C
0.058
<0.001
0.004
T3
SCL-K-9
0.2 (0.2) 0.5 (0.4) 0.9 (0.4) <0.001 A vs B
A vs C
B vs C
0.027
<0.001
0.042
T3
EQ-5D
93.5 (7.0) 89.3 (8.3) 64.4 (17.4) <0.001 A vs B
A vs C
B vs C
0.814
<0.001
<0.001
EQ-5D = EuroQuol (range 0–100; community-based standard value = 91.7); p = level of significance; SCL-K-9 = the Symptom Checklist (community-based standard value
= 0.41; higher values indicating greater distress); SD = standard deviation; T1–T3 = measurement time-points;
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social support [32, 33], are essential to coping successfully
with the transplant experience.
As a second analytical step, we sought to identify dif-
ferences between the cluster groups and thereby detect
those with poor post-transplant trajectories. Our patients
with poor postoperative HRQoL generally were older, were
more likely to suffer from more severe disease, had more
comorbid conditions, were more likely to have had pro-
longed ICU and hospital stays, had more hospital admis-
sions after transplantation and were more frequently treated
Table 3: Sociodemographic and medical characteristics of post-transplant outcome-clusters.
Optimal cluster (A)
n = 17 (42%)
Good cluster (B)
n = 14 (35%)
Poor cluster (C)
n = 9 (23%)
Effect size p-value
Sex 0.17a 0.551a
Male 11 27.5% 7 17.5% 4 10 %
Female 6 15% 7 17.5% 5 12.5%
Age (years; mean, SD) 46.5 16.6 44.2 13.9 54.6 15.4 0.07b 0.286b
Underlying diagnosis* (n, %) 0.34a 0.160a
COPD 9 22.5% 3 7.5% 3 7.5%
Cystic fibrosis 6 15% 6 15% 1 2.5%
Idiopathic pulmonary fibrosis 2 5% 2 5% 3 7.5%
Other 0 0 3 7.5% 2 5%
Disease severityc (mean, SD) 1.8 0.6 1.9 0.3 2.3 0.5 0.13b 0.075b
Time on waiting list (days, mean,
SD)
258.3 288.5 313.4 210.4 226.7 77.9 0.02b 0.700b
ECMO use (n, %) 6 15% 4 10% 3 7.5% 0.08a 0.883a
Comorbidities (mean, SD) 1.7 1.2 1.8 1.3 2.3 1.1 0.06b 0.386b
Number of days in ICU pLTx
(mean, SD)
5.8 5.5 5.9 4.6 10.4 11.0 0.08b 0.210b
Length of stay (weeks; mean,
SD)
4.4 1.4 4.6 1.4 9.6 3.6 0.53b 0.001b
Number of hospitalisations pLTx
(M, SD)
0.50 0.6 0.50 0.7 2.0 1.2 0.24b 0.006b
Number of infections pLTx
(mean, SD)
0.5 0.7 0.7 1.1 0.7 0.9 0.01b 0.836b
Number of rejections pLTx (m,
SD)
0.1 0.5 0.1 0.3 0.1 0.3 0.01b 0.943b
Antidepressants pLTx (n, %) 3 7.5% 1 2.5% 6 15% 0.53a 0.004a
COPD = chronic obstructive pulmonary disease; ECMO = extracorporal membrane oxygenation; ICU = intensive care unit; pLTx = post-transplant; SD = standard
deviation.
a Chi-square test for comparison of nominal or dichotomised variables and Cramer’s V for computing effect sizes.
b F-test for multiple comparison analysis of variance with continuous variables and Eta2 for computing effect sizes.
c Disease severity refers to the pretransplant health status while on waiting list and was judged by the treating pneumonologist (M.S.) into one of three categories (1–3).
Higher values indicate higher disease severity. 1 = patients with progressive lung diseases, some required oxygen therapy but predominantly treated as out-patients; 2 =
patients with progressive lung disease and oxygen therapy in bad health condition, partly treated as out-patients and partly transferred to inpatient hospital care; 3 =
patients with progressive lung disease in extremely critical health conditions (ICU, ECMO use; intubation, decarboxylation device).
Statistical significance: p <0.05.
Table 4: Predictor analyses for psychological distress and health-related quality of life 6 months post-transplant.
Medical factors T3
SCL-K-9
(n = 40)
T3
EQ-5D
(n = 40)
Age 0.25 –0.20
Sex† –0.13 –0.12
Disease severity 0.39* –0.42**
Time on waiting list –0.02 0.24
ECMO use –0.02 0.29
Comorbidities 0.16 –0.05
Number of days in ICU 0.11 –0.36*
Length of hospital stay 0.44* –0.72**
Number of hospitalisations pLTx 0.66** –0.43**
Number of infections pLTx 0.30 –0.13
Number of rejections pLTx 0.67 –0.18
Antidepressants pLTx† 0.47** –0.63**
T1 EQ-5D –0.37* 0.39*
ECMO = extracorporal membrane oxygenation; EQ-5D = EuroQuol (range 0–100; community-based standard value = 91.7); ICU = intensive care unit; pLTX = post-
transplant; SCL-K-9 = the Symptom Checklist (community-based standard value = 0.41; higher values indicating greater distress); T1,T3 = measurement time-points
* p ≤0 .05; ** p ≤0.01; *** p ≤0.001.
† Statistical relationship computed with Spearman Correlation.
Sex: 1 = male; 2 = female.
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with antidepressants. Previous studies have suggested a
negative impact of comorbidities on HRQoL after lung
transplant [13, 16]. Our results are consistent with these
findings, indicating that clinical complications (e.g., great-
er disease severity, a higher number of comorbidities, and
longer hospital stays) are associated with progressive qual-
ity of life deterioration over the early post-transplant peri-
od. With regards to demographic variables, in the
psychosocial transplant literature reduced HRQoL-gains
have been commonly described in older lung transplant re-
cipients, presumably because older patients have less en-
ergy and reserves to cope with the taxing post-operative
period than those who are younger [14, 34]. On the other
hand, researchers have reported significant gender differ-
ences in overall HRQoL, reflecting better outcomes in men
[15, 35]; notwithstanding, we did not observe this in the
current study.
Lastly, we explored potential predictors of psychological
distress and poor HRQoL 6 months after transplantation.
In particular, disease severity, the number of days spent
in the ICU and hospital, self-reported HRQoL 2 weeks
post-transplant, number of post-transplant hospital admis-
sions as well as use of antidepressants predicted impaired
HRQoL at 6 months of follow-up. Meanwhile, disease
severity, length of hospital stay, self-reported HRQoL 2
weeks post-transplant, number of hospital admissions, and
use of antidepressants significantly predicted levels of psy-
chological distress at 6 months. Age, gender, time on the
waiting list, preoperative ECMO use, the number of co-
morbid conditions, number of infections or rejections failed
to predict 6-month levels of psychological distress or
HRQoL. Our findings are similar to those of an earlier
cross-sectional cohort study investigating HRQoL determ-
inants among patients between 1 and 5 years since their
lung transplant, suggesting that lung disease and events
leading to hospitalisation negatively affect most of the
SF-36 (Short Form Health Survey) domains, whereas other
variables like age, gender and FEV1 exert little to no influ-
ence on HRQoL [34].
Taken together, almost a quarter of the investigated patients
suffered from elevated distress and substantially impaired
quality of life, with no considerable improvements over
time. This result is of high clinical importance, given that
elevated psychological distress and impaired HRQoL in the
early postoperative phase can have a persistent negative
impact upon long-term mental health and HRQoL [36].
Furthermore, a growing body of literature suggests that
early post-transplant depression and psychological distress
significantly increase the risk for long-term transplant-re-
lated morbidity and mortality [37–39]. Thus, the preco-
cious identification of transplant recipients with clinically
significant distress and impaired HRQoL is critical to ini-
tiate pharmacological and psychotherapeutic interventions
for these patients in order to reduce their symptom experi-
ence.
Study strengths and limitations
Strengths of the current study include our investigation of a
lung transplant population treated exclusively by the trans-
plant centre using a prospective, longitudinal study design,
as well the use of a rigorous statistical methodology to
identify distinct cluster groups, and the utilisation of val-
idated outcome measures with well-known psychometric
properties. Potential limitations include the relatively small
study sample. Because of the small sample, our results lack
statistical power, meaning that the results of our cluster
analyses were presented only descriptively. Moreover, we
surveyed lung transplant recipients over a relatively short
period of time (only 6 months). The follow-up of lung
transplant recipients over several years would add further
insights into the development of post-transplant psychoso-
cial trajectories and outcome predictors. Although our find-
ings should be interpreted with caution owing to these lim-
itations, we believe that our study provides realistic and
valid predictors for early post-operative psychosocial out-
comes.
Conclusions
The assessment of post-transplant psychological distress
and HRQoL in terms of cluster analyses instead of con-
sidering only outcomes at discrete time points is beneficial
in identifying patients who experience no significant post-
operative improvement in HRQoL. Psychosocial care of
transplant recipients who suffer from emotional distress
and impaired HRQoL is critical to maximizing recovery
and outcomes. Additional longitudinal research with larger
samples remains necessary to clarify the long-term post-
transplant outcomes of these patients and to identify other
potentially important outcome predictors.
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Figures (large format)
Figure 1
Patient recruitment.
LTx = lung transplantation; pLTx = post lung transplantation; T1–T3 = three measurement time-points.
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Figure 2
Post-transplant outcome clusters in lung transplant recipients.
Plots A–C illustrate postoperative outcome clusters after lung transplant determined by cluster analysis. The left y-axis represents mean values
for EQ-5D, while the right y-axis represents mean values for global SLK-9 values. Higher values indicate higher EQ-5D or poorer SCL-K-9
values, respectively. T1–T3 stand for the three different measurement time points (T1: 2 weeks; T2: 3 months; T3: 6 months post-transplant).
EQ-5D = the EuroQOL five-dimension Health-Related Quality of Life questionnaire; SCL-K-9 =Symptom Checklist short version-9
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